We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

227 hedge funds and large institutions have $1.56B invested in Syndax Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 72 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $25M | Put options by funds: $12.5M

63% more capital invested

Capital invested by funds: $953M → $1.56B (+$603M)

46% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 28

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

13% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 72

5% more funds holding

Funds holding: 216 → 227 (+11)

0.85% less ownership

Funds ownership: 118.22% → 117.38% (-0.85%)

Holders
227
Holders Change
+11
Holders Change %
+5.09%
% of All Funds
2.98%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.13%
New
41
Increased
81
Reduced
72
Closed
28
Calls
$25M
Puts
$12.5M
Net Calls
+$12.5M
Net Calls Change
+$10.7M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$27.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$24.6M
3
MB
MPM BioImpact
Massachusetts
+$18M
4
N
Nuveen
North Carolina
+$15.8M
5
SCM
Soleus Capital Management
Connecticut
+$12M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$24M
2
SFM
Sphera Funds Management
Israel
-$15.5M
3
SI
Sofinnova Investments
California
-$14.3M
4
SC
Stempoint Capital
New York
-$13.2M
5
EP
Eversept Partners
New York
-$7.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$5.89M -$123K -9,400 -2%
Aberdeen Group
52
Aberdeen Group
United Kingdom
$5.74M +$908K +69,366 +23%
Barclays
53
Barclays
United Kingdom
$5.35M -$457K -34,905 -9%
Capital Fund Management (CFM)
54
Capital Fund Management (CFM)
France
$5.25M +$2.13M +162,905 +91%
IC
55
Ikarian Capital
Texas
$5.13M +$4.37M +333,733 New
Walleye Capital
56
Walleye Capital
New York
$4.58M +$938K +71,643 +32%
BFM
57
Boothbay Fund Management
New York
$4.03M +$1.74M +133,088 +103%
PHS
58
PFM Health Sciences
California
$3.95M +$3.36M +256,488 New
JP Morgan Chase
59
JP Morgan Chase
New York
$3.91M -$249K -19,024 -7%
Hudson Bay Capital Management
60
Hudson Bay Capital Management
Connecticut
$3.85M -$2.53M -193,300 -44%
CSS
61
Cubist Systematic Strategies
Connecticut
$3.8M +$926K +70,749 +40%
Marshall Wace
62
Marshall Wace
United Kingdom
$3.6M +$24.2K +1,850 +0.8%
Canada Pension Plan Investment Board
63
Canada Pension Plan Investment Board
Ontario, Canada
$3.53M +$3.01M +229,600 New
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$3.51M -$1.61M -123,263 -35%
SGA
65
Sector Gamma AS
Norway
$3.24M +$2.76M +210,814 New
TCM
66
Tang Capital Management
California
$3.08M – – –
VIG
67
Vienna Insurance Group
Poland
$3.08M – – –
Macquarie Group
68
Macquarie Group
Australia
$2.77M – – –
EGM
69
Engineers Gate Manager
New York
$2.76M +$1.18K +90 +0.1%
Man Group
70
Man Group
United Kingdom
$2.69M -$697K -53,216 -23%
Swiss National Bank
71
Swiss National Bank
Switzerland
$2.44M -$75.9K -5,800 -4%
PAM
72
Panagora Asset Management
Massachusetts
$2.39M +$2.03M +155,316 New
KeyBank National Association
73
KeyBank National Association
Ohio
$2.31M +$1.96M +150,000 New
HF
74
HRT Financial
New York
$2.28M +$275K +21,028 +17%
Rafferty Asset Management
75
Rafferty Asset Management
New York
$2.18M +$207K +15,777 +13%
1 2
3
4 5

SNDX Hedge Fund Activity: Q3 2025 in Review

227 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2025, worth a combined $1.56B — up 63% from $953M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new SNDX positions and 28 closed out — a net gain of 13 holders — while 81 added to existing stakes and 72 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $27.8M. The largest seller was BlackRock, cutting an estimated $24M.

  • 227 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2025, up from 216 in Q2 2025.
  • Funds reported $1.56B of Syndax Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
  • 41 funds opened new Syndax Pharmaceuticals positions in Q3 2025 and 28 closed out, a net change of +13 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2025 was Point72 Asset Management, an estimated $27.8M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2025 was BlackRock, an estimated $24M sold.

Based on aggregated 13F filings for Q3 2025.